Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ABSTRAL vs A-HYDROCORT
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Fentanyl is a potent mu-opioid receptor agonist, producing analgesia and sedation by activating G-protein coupled opioid receptors in the central nervous system.
Hydrocortisone is a corticosteroid hormone that binds to glucocorticoid receptors, modulating gene expression to suppress inflammation, inhibit immune response, and regulate metabolism.
Management of breakthrough pain in cancer patients aged 18 and older who are already receiving and tolerant to around-the-clock opioid therapy for their underlying persistent cancer pain.
Adrenocortical insufficiency (primary and secondary),Congenital adrenal hyperplasia,Inflammatory conditions (e.g., rheumatoid arthritis, ulcerative colitis),Allergic reactions (severe),Asthma exacerbations,Dermatologic disorders (topical use),Ophthalmic inflammation (ophthalmic use)
For breakthrough pain in opioid-tolerant patients: initial dose 100 mcg sublingual tablet, titrate across strengths (100, 200, 300, 400, 600, 800 mcg) as needed; maximum 2 doses per episode, minimum 2 hours between episodes.
Adrenal insufficiency: oral 20-30 mg/day in divided doses; inflammatory conditions: 5-60 mg/day oral; IV/IM: hydrocortisone sodium succinate 50-100 mg every 4-6 hours.
Terminal elimination half-life: 6-10 hours (mean 8 hours); prolonged in elderly and hepatic impairment
Terminal half-life: 1.5-2 hours (cortisol); clinical effect persists 8-12 hours due to glucocorticoid receptor binding
Hepatic metabolism primarily via CYP3A4; major metabolites include norfentanyl (inactive) and other minor metabolites.
Primarily hepatic via CYP3A4 and other CYP450 enzymes, with reduction in the A-ring to inactive metabolites (e.g., tetrahydrocortisol).
Renal: ~70% as metabolites (primarily fentanyl conjugates and norfentanyl), ~10% unchanged; Fecal: ~9%; Biliary: minimal
Renal (primarily as metabolites, <1% unchanged); biliary/fecal (<5%)
80-85% bound primarily to albumin and alpha-1-acid glycoprotein
90-95% bound to corticosteroid-binding globulin (CBG) and albumin
4-6 L/kg; large Vd indicates extensive tissue distribution
0.5-0.8 L/kg; represents distribution into total body water, higher in obesity
Sublingual: 70-90% (mean 80%); buccal: 50-65%; oral: ~30% due to first-pass metabolism
Oral: 96% (well absorbed); IM/IV: 100%; topical: minimal systemic absorption (<1% with intact skin)
No specific GFR-based dose adjustment recommended; use caution in severe renal impairment (Cr Cl <30 m L/min) due to potential accumulation of fentanyl.
No specific adjustment required; monitor fluid/electrolytes in severe renal impairment.
For Child-Pugh Class A or B: no adjustment required; for Child-Pugh Class C: reduce dose and monitor closely for toxicity due to reduced clearance.
Dose reduction may be necessary in severe hepatic impairment; caution as metabolism is hepatic.
Not approved for pediatric patients <18 years; safety and efficacy not established.
Doses are weight-based; for adrenal insufficiency: 0.5-0.75 mg/kg/day in divided doses; for anti-inflammatory: 0.5-10 mg/kg/day.
Initiate at the lowest available dose (100 mcg) and titrate cautiously; elderly patients may have altered pharmacokinetics and increased sensitivity to fentanyl.
Use lowest effective dose; monitor for osteoporosis, hypertension, and glucose intolerance.
Risk of respiratory depression, addiction, abuse, and misuse; risk of accidental ingestion; risk of medication errors resulting in fatal overdose; life-threatening respiratory depression in opioid-non-tolerant patients; risk of opioid analgesic drug interactions with CNS depressants; risk of neonatal opioid withdrawal syndrome with prolonged use during pregnancy.
None.
Respiratory depression, QT prolongation, serotonin syndrome, adrenal insufficiency, severe hypotension, seizures, biliary tract disease, gastrointestinal obstruction, withdrawal syndrome, and risk of overdose with alcohol or other CNS depressants.
Immunosuppression and increased infection risk,Adrenal suppression with prolonged use,Cushing's syndrome with chronic use,Osteoporosis with long-term use,GI perforation risk in inflammatory bowel disease,Growth suppression in children,Fetal harm (category C),Ocular effects (cataracts, glaucoma),Fluid and electrolyte disturbances
Hypersensitivity to fentanyl or any components; opioid-non-tolerant patients; acute or severe bronchial asthma; known or suspected gastrointestinal obstruction; concurrent use of MAOIs or within 14 days of discontinuation.
Systemic fungal infections,Hypersensitivity to hydrocortisone or any component,Administration of live or live-attenuated vaccines (relative),Herpes simplex keratitis (topical ophthalmic use),Peptic ulcer disease (relative),Uncontrolled hypertension (relative)
Avoid grapefruit and grapefruit juice during treatment as they inhibit CYP3A4, increasing fentanyl exposure. No other significant food interactions; however, avoid alcohol due to additive CNS depressant effects. Maintain consistent meal timing relative to dosing to minimize variability.
No specific food interactions. However, high-sodium foods may exacerbate fluid retention; a low-sodium diet is recommended if edema occurs. Grapefruit juice does not significantly affect hydrocortisone. Avoid alcohol due to additive gastric irritation.
FDA Pregnancy Category C. First trimester: Inadequate human data; opioid analgesics are not associated with major malformations but may cause neural tube defects at high doses in animal studies. Second trimester: No specific malformation risk. Third trimester: Prolonged use can cause neonatal opioid withdrawal syndrome (NOWS) and respiratory depression at birth.
Hydrocortisone is a corticosteroid. Use during first trimester is associated with increased risk of oral clefts (odds ratio 1.5-3.0). Second and third trimester use may cause fetal adrenal suppression, growth restriction, and premature birth. Risk of premature rupture of membranes and intrauterine growth restriction increases with prolonged use.
Minimal excretion into breast milk; M/P ratio not reported. Fentanyl is poorly absorbed orally, making significant infant exposure unlikely. Monitor infant for sedation, respiratory depression, and poor feeding. Avoid use in breastfeeding mothers with opioid dependence or high doses.
Hydrocortisone is excreted into breast milk in low concentrations. M/P ratio approximately 0.4-1.0. Doses up to 20 mg/day are considered compatible with breastfeeding. Higher doses may suppress infant adrenal function; monitor infant for growth and adrenal suppression.
Pregnancy increases clearance and volume of distribution, potentially reducing drug levels. Dose adjustments may be needed: initiate with lower doses and titrate to effect; consider increasing frequency or using breakthrough doses. Monitor for inadequate analgesia. Avoid abrupt discontinuation; taper if stopping.
Due to increased clearance and protein binding changes, doses may need to be increased by 50-100% in the second and third trimesters. Monitor clinical response and adjust dose accordingly. Stress doses (e.g., 50-100 mg IV) should be given during labor and delivery.
ABSTRAL (fentanyl sublingual spray) is a transmucosal immediate-release fentanyl (TIRF) formulation indicated for breakthrough pain in opioid-tolerant patients. Due to high bioavailability (~70%) and rapid onset (peak plasma concentration at 15-30 minutes), initial titration must start with 100 mcg, with dose escalation based on efficacy and tolerability. Weight-based conversion from other fentanyl products is not valid; utilize the provided conversion table. Patients must have a rescue agent (e.g., naloxone) available. Concomitant use with CYP3A4 inhibitors (e.g., ketoconazole, ritonavir) or inducers (e.g., rifampin, carbamazepine) requires dose adjustment. Avoid use in opioid-naïve patients due to risk of respiratory depression.
For acute adrenal insufficiency, give IV bolus of 100 mg hydrocortisone followed by 100 mg every 8 hours. Taper to oral replacement over days. In septic shock, stress-dose hydrocortisone (200 mg/day) may be used if vasopressor-dependent. Monitor for hyperglycemia, hypokalemia, and immunosuppression. Abrupt discontinuation can cause adrenal crisis.
Use only for breakthrough cancer pain while on around-the-clock opioid therapy.,Do not switch from other fentanyl products based on dose; follow specific conversion instructions.,Spray entire dose into mouth; do not swallow or rinse for at least 10 minutes.,Store at room temperature, away from children and pets.,Dispose of unused units via drug take-back program or by flushing down toilet per FDA guidelines.,Never share this medication with others; death may occur.,Seek emergency if severe drowsiness, confusion, or slow breathing occurs.
Take exactly as prescribed; do not stop suddenly without doctor's guidance.,Carry a medical alert card or bracelet indicating you take hydrocortisone.,Report signs of adrenal crisis: severe weakness, dizziness, nausea, vomiting, abdominal pain.,During illness or stress (e.g., surgery, infection), dose may need temporary increase; contact your doctor.,Avoid live vaccines during therapy.,Monitor for weight gain, swelling, mood changes, or high blood sugar symptoms (increased thirst, urination).
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ABSTRAL vs A-HYDROCORT, answered by our medical review team.
ABSTRAL is a Opioid Analgesic that works by Fentanyl is a potent mu-opioid receptor agonist, producing analgesia and sedation by activating G-protein coupled opioid receptors in the central nervous system.. A-HYDROCORT is a Corticosteroid that works by Hydrocortisone is a corticosteroid hormone that binds to glucocorticoid receptors, modulating gene expression to suppress inflammation, inhibit immune response, and regulate metabolism.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ABSTRAL and A-HYDROCORT depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ABSTRAL is: For breakthrough pain in opioid-tolerant patients: initial dose 100 mcg sublingual tablet, titrate across strengths (100, 200, 300, 400, 600, 800 mcg) as needed; maximum 2 doses per episode, minimum 2 hours between episodes.. The standard adult dose of A-HYDROCORT is: Adrenal insufficiency: oral 20-30 mg/day in divided doses; inflammatory conditions: 5-60 mg/day oral; IV/IM: hydrocortisone sodium succinate 50-100 mg every 4-6 hours.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ABSTRAL and A-HYDROCORT in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ABSTRAL is classified as Category C. FDA Pregnancy Category C. First trimester: Inadequate human data; opioid analgesics are not associated with major malformations but may cause neural tube defects at high doses in a. A-HYDROCORT is classified as Category C. Hydrocortisone is a corticosteroid. Use during first trimester is associated with increased risk of oral clefts (odds ratio 1.5-3.0). Second and third trimester use may cause fetal. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.